CA2363999A1 - Peptides of the at1 receptor and their use for preeclampsia and malign hypertension - Google Patents
Peptides of the at1 receptor and their use for preeclampsia and malign hypertension Download PDFInfo
- Publication number
- CA2363999A1 CA2363999A1 CA002363999A CA2363999A CA2363999A1 CA 2363999 A1 CA2363999 A1 CA 2363999A1 CA 002363999 A CA002363999 A CA 002363999A CA 2363999 A CA2363999 A CA 2363999A CA 2363999 A1 CA2363999 A1 CA 2363999A1
- Authority
- CA
- Canada
- Prior art keywords
- peptides
- antibodies
- receptor
- preeclampsia
- auto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 60
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 45
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 34
- 206010020772 Hypertension Diseases 0.000 title claims description 13
- 230000001575 pathological effect Effects 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000008030 elimination Effects 0.000 claims description 6
- 238000003379 elimination reaction Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000010839 body fluid Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 101710120037 Toxin CcdB Proteins 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 101150059573 AGTR1 gene Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 4
- 102400000345 Angiotensin-2 Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 230000035559 beat frequency Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000010349 pulsation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000032749 Pregnancy Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229940106135 cellulose Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19860320.7 | 1998-12-24 | ||
| DE19860320 | 1998-12-24 | ||
| DE19954305A DE19954305A1 (de) | 1998-12-24 | 1999-11-11 | Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie |
| DE19954305.4 | 1999-11-11 | ||
| PCT/DE1999/004112 WO2000039154A2 (de) | 1998-12-24 | 1999-12-22 | Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2363999A1 true CA2363999A1 (en) | 2000-07-06 |
Family
ID=26051071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002363999A Abandoned CA2363999A1 (en) | 1998-12-24 | 1999-12-22 | Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1141018A2 (de) |
| JP (1) | JP2002539075A (de) |
| AU (1) | AU2429100A (de) |
| CA (1) | CA2363999A1 (de) |
| WO (1) | WO2000039154A2 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110374B2 (en) | 2001-05-11 | 2012-02-07 | Cell Trend GmbH | Method for predicting the risk of transplant rejection and immunological testkit |
| US8425877B2 (en) | 2006-08-04 | 2013-04-23 | Celltrend Gmbh | Method for diagnosis of systemic sclerosis involving an anti-AT1-receptor antibody |
| CN109467599A (zh) * | 2017-09-08 | 2019-03-15 | 武汉华纪元生物技术开发有限公司 | 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314811A1 (en) * | 2000-08-02 | 2002-02-02 | Brian Archibald Macvicar | Autoimmunity to angiotensin at1 receptors in schizophrenia |
| EP1570272A2 (de) | 2002-11-29 | 2005-09-07 | Max-Delbrück-Centrum Für Molekulare Medizin | Bestimmung agonistischer autoantikörper |
| DE10327066A1 (de) * | 2002-11-29 | 2004-09-16 | Max-Delbrück-Centrum für Molekulare Medizin | Bestimmung agonistischer Autoantikörper |
| EP1884776A1 (de) | 2006-08-04 | 2008-02-06 | Celltrend GmbH | Verfahren zur diagnose einer krankheit, die auf der gegenwart des anti-endothelin-antikörpers beruht |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025482A1 (en) * | 1993-04-23 | 1994-11-10 | Evans Herbert J | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
| DE19826442A1 (de) * | 1998-06-02 | 1999-12-09 | Affina Immuntechnik Gmbh | Rational designte Peptide, ihre Herstellung und ihre Verwendung |
-
1999
- 1999-12-22 EP EP99967916A patent/EP1141018A2/de not_active Withdrawn
- 1999-12-22 JP JP2000591065A patent/JP2002539075A/ja active Pending
- 1999-12-22 AU AU24291/00A patent/AU2429100A/en not_active Abandoned
- 1999-12-22 WO PCT/DE1999/004112 patent/WO2000039154A2/de active Application Filing
- 1999-12-22 CA CA002363999A patent/CA2363999A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110374B2 (en) | 2001-05-11 | 2012-02-07 | Cell Trend GmbH | Method for predicting the risk of transplant rejection and immunological testkit |
| US8425877B2 (en) | 2006-08-04 | 2013-04-23 | Celltrend Gmbh | Method for diagnosis of systemic sclerosis involving an anti-AT1-receptor antibody |
| CN109467599A (zh) * | 2017-09-08 | 2019-03-15 | 武汉华纪元生物技术开发有限公司 | 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用 |
| CN109467599B (zh) * | 2017-09-08 | 2021-06-04 | 武汉华纪元生物技术开发有限公司 | 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2429100A (en) | 2000-07-31 |
| JP2002539075A (ja) | 2002-11-19 |
| WO2000039154A3 (de) | 2000-09-21 |
| EP1141018A2 (de) | 2001-10-10 |
| WO2000039154A8 (de) | 2001-02-15 |
| WO2000039154A2 (de) | 2000-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002244968B2 (en) | Anti-osteopontin antibody and use thereof | |
| CN101215323B (zh) | 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 | |
| Wang et al. | Amino acid sequences at constant and variable regions of heavy chains of monotypic immunoglobulins G and M of a single patient | |
| US20090220469A1 (en) | Peptides against autoantibodies associated with glaucoma and use of these peptides | |
| CA2363999A1 (en) | Peptides of the at1 receptor and their use for preeclampsia and malign hypertension | |
| Baxevanis et al. | Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis | |
| US7745139B1 (en) | Peptides of the AT1 receptor and their uses | |
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| RU2006101992A (ru) | Агонист-полипептид рецептора для зота и зонулина | |
| JP4218987B2 (ja) | ペプチド免疫療法治療剤 | |
| JP3174041B2 (ja) | 抗ヒト絨毛性性腺刺激ホルモン（ｈＣＧ）抗体 | |
| CN114957438B (zh) | 用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法 | |
| JP5671347B2 (ja) | アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド | |
| JP2000221191A (ja) | ヒト障害についての診断マ―カ― | |
| US20090186044A1 (en) | Type iv collagen-like immunoreactive peptide | |
| Mihelić et al. | Distribution and biological activity of β-thymosins | |
| Wallukat et al. | Peptides of the AT 1 receptor and their uses | |
| JP3271159B2 (ja) | レニン活性物質 | |
| CN108948183B (zh) | α1受体和AT1受体抗原类似物多肽及其抗体检测试剂盒和应用 | |
| KR101156523B1 (ko) | 아토피성 피부염 유도 물질 | |
| AU2002242273B2 (en) | Compositions of multimeric profilin for diagnosis and treatment of allergies | |
| CN114920851B (zh) | Aβ1-42抗原及其检测阿尔茨海默患者体内Aβ1-42浓度的用途 | |
| WO2024122553A1 (ja) | 潰瘍性大腸炎又は原発性硬化性胆管炎の治療方法 | |
| CN101928333A (zh) | 一种人eif4h多肽及其抗体制备方法 | |
| CN108148125A (zh) | 一种人eif4h多肽及其抗体制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20121224 |